ImmunoCreate Overview
- Year Founded
-
2012
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$50K
- Investors
-
1
ImmunoCreate General Information
Description
Developer of a Beta-actin monoclonal antibody designed for the diagnosis and treatment of neurofibromatosis. The company is currently operating in Stealth mode.
Contact Information
Corporate Office
- 100 Oxmoor Road
- Suite 110
- Birmingham, AL 35209
- United States
Corporate Office
- 100 Oxmoor Road
- Suite 110
- Birmingham, AL 35209
- United States
ImmunoCreate Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | 01-Oct-2024 | $50K | Completed | Stealth |
ImmunoCreate Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Innovation Depot | Accelerator/Incubator | Minority |
ImmunoCreate FAQs
-
When was ImmunoCreate founded?
ImmunoCreate was founded in 2012.
-
Where is ImmunoCreate headquartered?
ImmunoCreate is headquartered in Birmingham, AL.
-
What industry is ImmunoCreate in?
ImmunoCreate’s primary industry is Pharmaceuticals.
-
Is ImmunoCreate a private or public company?
ImmunoCreate is a Private company.
-
What is the current valuation of ImmunoCreate?
The current valuation of ImmunoCreate is .
-
What is ImmunoCreate’s current revenue?
The current revenue for ImmunoCreate is .
-
How much funding has ImmunoCreate raised over time?
ImmunoCreate has raised $50K.
-
Who are ImmunoCreate’s investors?
Innovation Depot has invested in ImmunoCreate.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process